{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:34:53Z","timestamp":1791977693525,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010342","name":"Gillbergska stiftelsen","doi-asserted-by":"publisher","award":["Gillbergska stiftelsen"],"award-info":[{"award-number":["Gillbergska stiftelsen"]}],"id":[{"id":"10.13039\/100010342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala Universitet","doi-asserted-by":"publisher","award":["Uppsala Universitet"],"award-info":[{"award-number":["Uppsala Universitet"]}],"id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ethosuximide and other anti-epileptic drugs have been reported to cause idiosyncratic reactions such as lupus-like syndromes, with elevated antinuclear antibody (ANA) levels. Herein, we present a case of a girl who developed a very severe Raynaud\u2019s phenomenon reaction and anti-Scl-70 antibodies related to treatment with ethosuximide, due to juvenile absence epilepsy (JAE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 12-year-old girl was diagnosed with JAE and treatment with ethosuximide was initiated. Two and a half months later her fingers, digits II\u2013V bilaterally, began to ache and were discolored, alternatingly white, blue, or normal-colored. Two weeks later, her fingers were bluish-black, aching severely, almost continuously. The family sought medical advice. Ethosuximide was halted and due to the severe symptoms, treatment with both prednisolone and intravenous iloprost was commenced. Laboratory tests revealed high ANA levels with anti-Scl-70 pattern and confirmed anti-Scl-70 antibodies. After a few weeks, she started to improve and the symptoms slowly decreased over five months. Anti-Scl-70 was still detectable four months after onset of symptoms, though she was much improved. After eleven months, repeated ANA analyses were completely negative.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although extremely rare, it is important to recognize that severe Raynaud\u2019s phenomenon, threatening peripheral digital circulation, may occur as an idiosyncratic reaction to ethosuximide, raising concern over possible onset of vasculitis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-022-00782-8","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T23:02:17Z","timestamp":1671750137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Severe Raynaud\u2019s phenomenon from ethosuximide raised concern over possible onset of systemic vasculitis: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-0453","authenticated-orcid":false,"given":"Lillemor","family":"Berntson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Liminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"1","key":"782_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1358863X20983455","volume":"26","author":"E Choi","year":"2021","unstructured":"Choi E, Henkin S. Raynaud\u2019s phenomenon and related vasospastic disorders. Vasc Med. 2021;26(1):56\u201370.","journal-title":"Vasc Med"},{"key":"782_CR2","first-page":"CD003032","volume":"1","author":"F Brigo","year":"2021","unstructured":"Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2021;1:CD003032.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"782_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2169\/internalmedicine.35.527","volume":"35","author":"N Miyasaka","year":"1996","unstructured":"Miyasaka N. Drug-induced lupus. Intern Med. 1996;35(7):527\u20138.","journal-title":"Intern Med"},{"issue":"8","key":"782_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1001\/jama.1968.03140210087025","volume":"204","author":"S Livingston","year":"1968","unstructured":"Livingston S, Rodriguez H, Greene CA, Pauli LL. Systemic lupus erythematosus. Occurrence in association with ethosuximide therapy. JAMA. 1968;204(8):731\u20132.","journal-title":"JAMA"},{"issue":"4","key":"782_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0022-3476(70)80418-8","volume":"76","author":"IA Dabbous","year":"1970","unstructured":"Dabbous IA, Idriss HM. Occurrence of systemic lupus erythematosus in association with ethosuccimide therapy. Case report. J Pediatr. 1970;76(4):617\u201320.","journal-title":"J Pediatr"},{"issue":"1","key":"782_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00002826-199302000-00002","volume":"16","author":"VE Drory","year":"1993","unstructured":"Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol. 1993;16(1):19\u201329.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"782_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/acr2.11398","volume":"4","author":"B Jandali","year":"2022","unstructured":"Jandali B, Salazar GA, Hudson M, Fritzler MJ, Lyons MA, Estrada YMRM, et al. The effect of anti-scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis. ACR Open Rheumatol. 2022;4(4):345\u201351.","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"782_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1542\/peds.57.4.529","volume":"57","author":"BH Singsen","year":"1976","unstructured":"Singsen BH, Fishman L, Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics. 1976;57(4):529\u201334.","journal-title":"Pediatrics"},{"issue":"7","key":"782_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2169\/internalmedicine.35.587","volume":"35","author":"S Takeda","year":"1996","unstructured":"Takeda S, Koizumi F, Takazakura E. Ethosuximide-induced lupus-like syndrome with renal involvement. Intern Med. 1996;35(7):587\u201391.","journal-title":"Intern Med"},{"issue":"2","key":"782_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.alit.2021.08.005","volume":"71","author":"Y Hamaguchi","year":"2022","unstructured":"Hamaguchi Y. Drug-induced scleroderma-like lesion. Allergol Int. 2022;71(2):163\u20138.","journal-title":"Allergol Int"},{"issue":"1","key":"782_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/08916930400022947","volume":"38","author":"D Basu","year":"2005","unstructured":"Basu D, Reveille JD. Anti-scl-70. Autoimmunity. 2005;38(1):65\u201372.","journal-title":"Autoimmunity"},{"issue":"11","key":"782_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.autrev.2010.06.005","volume":"9","author":"M Mahler","year":"2010","unstructured":"Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-scl-70 (topo-I) antibodies in SLE: myth or reality? Autoimmun Rev. 2010;9(11):756\u201360.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"782_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E","volume":"43","author":"M Kuwana","year":"2000","unstructured":"Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 2000;43(5):1074\u201384.","journal-title":"Arthritis Rheum"},{"key":"782_CR14","doi-asserted-by":"publisher","first-page":"104040","DOI":"10.1016\/j.mvr.2020.104040","volume":"132","author":"R Taher","year":"2020","unstructured":"Taher R, Sara JD, Toya T, Shepherd R, Moder K, Lerman LO, et al. Secondary Raynaud\u2019s phenomenon is associated with microvascular peripheral endothelial dysfunction. Microvasc Res. 2020;132:104040.","journal-title":"Microvasc Res"},{"issue":"6","key":"782_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/BOR.0000000000000826","volume":"33","author":"AL Herrick","year":"2021","unstructured":"Herrick AL. Raynaud\u2019s phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol. 2021;33(6):453\u201362.","journal-title":"Curr Opin Rheumatol"},{"issue":"6 Suppl 86","key":"782_CR16","first-page":"183","volume":"32","author":"K Gerhold","year":"2014","unstructured":"Gerhold K, Becker MO. Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications. Clin Exp Rheumatol. 2014;32(6 Suppl 86):183.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00782-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-022-00782-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-022-00782-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T23:03:41Z","timestamp":1671750221000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-022-00782-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1186\/s12969-022-00782-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An ethical application sent to the Swedish Ethical Authorities was approved, EM 2021\u201302441. The patient is now 21 years old. Verbal informed assent and written informed consent were obtained from the patient on August 30, 2022.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}